Clinical Trials for Parkinson's Psychosis and Hallucinations
Some people with Parkinson's experience hallucinations or delusions, sometimes as a feature of the disease and sometimes as a side effect of medication. Parkinson's disease psychosis can be distressing for both patients and caregivers, and it is an active area of research.
Trials in this space test medications designed to reduce hallucinations without worsening movement symptoms, as well as studies that look at the causes and course of psychosis over time.
Below are the recruiting trials we track that focus on psychosis and hallucinations. Sign up to be emailed when a new one opens.
14 Recruiting Psychosis & Hallucinations Trials
- Testing new Parkinson treatment approach, NCT07488351, RECRUITING
- Assess confidence in thinking skills, NCT07488377, RECRUITING
- Link imagining movements to frailty, NCT07488364, RECRUITING
- Reduce movement problems with supplement, NCT07064005, PHASE1, RECRUITING
- Find safe gene therapy dose, NCT07371338, PHASE1, RECRUITING
- Reduce overactive dopamine related behaviors, NCT07151378, PHASE3, RECRUITING
- Improve access to specialist care, NCT05014971, RECRUITING
- Reduce hallucinations delusions and illusions, NCT05824728, PHASE2, RECRUITING
- Reduce motor symptoms using synbiotic, NCT05576818, PHASE3, RECRUITING
- Compare pimavanserin and quetiapine effectiveness, NCT05590637, PHASE4, RECRUITING
- Reduce movement slowness and fatigue, NCT06883266, RECRUITING
- Reduce hallucinations without worsening movement, NCT04373317, PHASE4, RECRUITING
- Identify signals predicting mood fluctuations, NCT07404241, RECRUITING
- Reduce depression anxiety and stress, NCT06821230, RECRUITING